As a world leader in serving science, Thermo Fisher Scientific has always been committed to providing innovative testing solutions to aid in proper disease diagnosis and patient management. When COVID-19 emerged, we applied that commitment to addressing the needs of the pandemic, from molecular testing to producing expanded volumes of viral transport media for sample collection.1 And now, we have developed and launched the Thermo Scientific™ OmniPATH™ COVID-19 Total Antibody ELISA test and Thermo Scientific™ EliA™ SARS-CoV-2-Sp1 IgG test.
The global scientific community has come together to address the COVID-19 pandemic at an unprecedented speed. As part of that community, we are aware this is a complex problem, and that our knowledge is constantly evolving. We recognize that there won’t be a single diagnostic solution that solves for all challenges.
That’s why we’re currently developing a portfolio of products to meet rapidly growing COVID-19 serological testing demands, rooted in our commitment to delivering scientific quality at the scale the world needs.
We help laboratories and clinicians put the patient first. The OmniPATH COVID-19 Total Antibody ELISA Test was developed with the patient’s path to testing in mind, as one piece of a larger portfolio of testing solutions still in development.
We characterize the use of COVID-19 serology in the following four categories: population monitoring, diagnosis, treatment, and immunity.
We characterize the use of COVID-19 serology into the following four categories:
From epidemiological studies to workforce monitoring, antibody testing is essential when it comes to tracking the pandemic and containing outbreaks. Serological tests can help identify how effective containment strategies have been and help identify what percentage of the population has seen the virus.2,3
A complex piece of the puzzle that hinges on when patients were first infected; serological testing can fill the gap for when it’s too late to detect live virus with molecular testing.4
Screening for convalescent plasma therapy relies on serology testing to detect individuals who have mounted a robust immune response to SARS-CoV-2.2
Although it is still too early to know if antibodies to SARS-CoV-2 confer lasting immunity, serological testing will still be essential for tracking whether natural immunity exists and understanding the efficacy of many vaccines in development.2,5
1. Thermo Fisher Scientific’s Support of COVID-19 Response Continues to Expand with U.S. Government Contract for Products Used in Sample Collection. https://thermofisher.mediaroom.com/2020-05-18-Thermo-Fisher-Scientifics-Support-of-COVID-19-Response-Continues-to-Expand-with-U-S-Government-Contract-for-Products-Used-in-Sample-Collection. Accessed August 2020.
2. Theel, E. S., et al. "The Role of Antibody Testing for SARS-CoV-2: Is There One?" Journal of Clinical Microbiology. 2020;58(8): e00797-00720.
3. Bohn, M. K., et al. "Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence." Clin Chem Lab Med. 2020;58(7): 1037-1052.
4. Kucirka, L. M., et al. "Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure." Ann Intern Med. 2020; doi:10.7326/M20-1495
5. Lerner, A. M., et al. "The COVID-19 Serology Studies Workshop: Recommendations and Challenges." Immunity. 2020; https://doi.org/10.1016/j.immuni.2020.06.012